Third-Line’s A Charm: Amgen Aims To Take A BiTE Out Of Pretreated SCLC
Executive Summary
The company presented data for its bispecific antibody tarlatamab at WCLC, drawing noticeably more excitement than highly anticipated but disappointing data for Lumakras with checkpoint inhibitors.
You may also be interested in...
ESMO 2023: Tarlatamab Primed To Take Big BiTE Out Of SCLC Market
Amgen's DLL3-targeting bispecific T-cell engager could be filed on Phase II data having demonstrated exceptional duration of response in small cell lung cancer patients.
Amgen’s US Amjevita Sales Slow While Other Growth Drivers Deliver
Sales of the Humira biosimilar increased double digits globally year over year, but declined 63% in the US versus Q1 due to inventory stockpiling.
Genentech Licenses Prostate Cancer Drug From China-Based Jemincare
Deal Snapshot: Other major players have made headway in bispecifics for prostate cancer, while Jemincare’s drug is the latest China-developed technology to head westward.